Your browser doesn't support javascript.
loading
Outcomes of Chronic Total Occlusion Percutaneous Coronary Intervention of the Left Anterior Descending Artery.
Megaly, Michael; Zakhour, Samer; Karacsonyi, Judit; Basir, Mir B; Kunkel, Katherine; Gupta, Ankur; Neupane, Saroj; Alqarqaz, Mohammad; Brilakis, Emmanouil S; Alaswad, Khaldoon.
Afiliação
  • Megaly M; Division of Cardiology, Henry Ford Hospital, Detroit, Michigan.
  • Zakhour S; Division of Cardiology, Henry Ford Hospital, Detroit, Michigan.
  • Karacsonyi J; Department of Cardiology, Minneapolis Heart Institute, Abbott Northwestern Hospital, Minneapolis, Minnesota.
  • Basir MB; Division of Cardiology, Henry Ford Hospital, Detroit, Michigan.
  • Kunkel K; Department of Cardiology, Piedmont Heart Institute, Atlanta, Georgia.
  • Gupta A; Department of Cardiology, HonorHealth Heart Group - Shea, Phoenix, Arizona.
  • Neupane S; Department of Cardiology, WakeMed Hospital, Raleigh, North Carolina.
  • Alqarqaz M; Division of Cardiology, Henry Ford Hospital, Detroit, Michigan.
  • Brilakis ES; Department of Cardiology, Minneapolis Heart Institute, Abbott Northwestern Hospital, Minneapolis, Minnesota.
  • Alaswad K; Division of Cardiology, Henry Ford Hospital, Detroit, Michigan. Electronic address: kalaswad@gmail.com.
Am J Cardiol ; 193: 75-82, 2023 04 15.
Article em En | MEDLINE | ID: mdl-36878056
ABSTRACT
The left anterior descending artery (LAD) subtends a large myocardial territory. The outcomes of LAD chronic total occlusion (CTO) percutaneous coronary intervention (PCI) have received limited study. We performed a retrospective analysis of all patients who underwent LAD CTO PCI at a high-volume single center. Outcomes included in-hospital and long-term major adverse cardiovascular events (MACEs) and changes in left ventricular ejection fraction (LVEF). We performed a subgroup analysis of patients with ischemic cardiomyopathy, defined as an LVEF of 40% or less. From December 2014 to February 2021, 237 patients underwent LAD CTO PCI. The technical success rate was 97.4%, and the in-hospital MACE rate was 5.4%, A landmark analysis after hospital discharge showed an overall survival of 92% and 85% MACE-free survival at 2 years. There was no difference in overall survival or MACE-free survival between those who had ischemic cardiomyopathy versus those who did not. In patients with ischemic cardiomyopathy, LAD CTO PCI was associated with significant improvement in LVEF (10.9% at 9 months), which was further pronounced when these patients had a proximal LAD CTO and were on optimal medical therapy (14% at 6 months). In a single high-volume center, LAD CTO PCI was associated with 92% overall survival at 2 years, with no difference in survival between patients with or without ischemic cardiomyopathy. LAD CTO PCI was associated with an absolute 10% increase in LVEF at 9 months in patients with ischemic cardiomyopathy.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Oclusão Coronária / Intervenção Coronária Percutânea / Cardiomiopatias Tipo de estudo: Diagnostic_studies / Etiology_studies / Observational_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: Am J Cardiol Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Oclusão Coronária / Intervenção Coronária Percutânea / Cardiomiopatias Tipo de estudo: Diagnostic_studies / Etiology_studies / Observational_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: Am J Cardiol Ano de publicação: 2023 Tipo de documento: Article